22 May 2013
Keywords: USA, FDA, Post-marketing oversight, Monitoring, CDER
Article | 23 April 2012
In what is seen as a response to criticism that the agency lacks teeth in monitoring drugs once they are ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 April 2012
21 May 2013
© 2013 thepharmaletter.com